Dear Valued Shareholders,

This is the news you’ve been waiting for.

Optimi Health today announced that it has entered into a $1.2 million CAD definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research and clinical trials.

At this time, we are respecting the client’s wish to remain private and look forward to sharing more news on this exciting announcement at a future date and time.

Optimi will cultivate dried GMP psilocybin-containing biomass and extract it into a refined substance, which will be distributed to the client’s international research sites. This announcement affirms Optimi’s commitment to GMP production with capabilities to supply large scale, research and development programs.

“This is a big day for Optimi, and to be selected as the singular supply entity in the sector capable of scaling to help fulfill the needs of our client reflects our ability to deliver substantial value to the research community and our shareholders,” said Optimi CEO, Bill Ciprick.

This latest agreement has helped to fulfill the goal of Optimi Health’s Founders in making the company a true multinational participant in the research and development of psychedelic medicines.

Your ongoing support and belief in Optimi have helped us get to where we are today.

A copy of today’s press release can be found on our website at www.optimihealth.ca/news-and-updates/

Thank you.

Earnings Results

Optimi plans to report its Q2 2023 earnings results before markets open on a date soon to be approved (between May 19 – 30, 2023) by Optimi’s Audit Committee.

A complete End Of Year financial report will be made available on September 30, 2023, in order to provide a comprehensive picture of earnings from these ongoing agreements.

Questions related to this announcement should be directed to: investors@optimihealth.ca

A New Face at Optimi:

We are pleased to announce that effective May 7, 2023, Karina Lahnakoski will be joining us full time as the “Director of Quality and Commercial Strategies”. In this newly created position, she will be responsible for overseeing the QA/QC functions for Optimi Labs Inc. and providing overall direction for Quality Management Systems to support the life cycle development of Optimi’s products.

In addition, Karina will be responsible for ensuring systems are in place for the testing and documentation of products manufactured, provide strategic direction, risk management, oversight, project management, and commercial planning for Optimi. As we begin to fully scale the operation, this will be a critical leadership role to keep us on track and GMP compliant with everything we do. Karina will assume a leadership role in coordinating efforts from production, labs and quality and will be an active member of leadership to report to Senior Leadership on operational progress.

Karina has a great background starting with a BSc. (Hons) in Biochemistry, is a certified Project Management Professional (PMP), ICD Certified (Institute of Corporate Directors) and a MBA from Schulich School of Business.